AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 29353388
Drug: Ultrasound-guided injection
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided injection with 5 ml of 1% lidocaine and 80 mg of methylprednisolone
Trial: 29353388
Drug: Conventional anatomic
RxNorm normalized name: Atomic Balm
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional anatomic landmark palpation guidance injection with 5 ml of 1% lidocaine and 80 mg of methylprednisolone
Trial: 29353388
Drug: Conventional anatomic
RxNorm normalized name: Atomic Balm
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional anatomic landmark palpation guidance injection
Trial: 26861113
Drug: Drug-Eluting Stents
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-Eluting Stents (DES) with paclitaxel
Trial: 16959672
Drug: Constraint-Induced Movement
RxNorm normalized name: constant albicans extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constraint-Induced Movement Therapy (CI therapy) for subacute therapy group (3 to 9 months after stroke)
Trial: 16959672
Drug: Constraint-Induced Movement
RxNorm normalized name: constant albicans extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constraint-Induced Movement Therapy (CI therapy) for chronic therapy group (1 year after stroke)
Trial: 16959672
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of subacute and chronic therapy groups
Trial: 14594455
Drug: Nutritional supplement
RxNorm normalized name: Nutritional supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional supplement containing lutein, vitamins A, C and E, zinc, and copper
Trial: 10671945
Drug: IGF‐I 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IGF‐I 50 microg/kg subcutaneously thrice daily during a six day study period
Trial: 10671945
Drug: IGF‐I treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IGF‐I treatment
Trial: 1341893
Drug: Bretylium tosylate
RxNorm normalized name: Bretylium Tosylate
DrugBank: Bretylium (DB01158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bretylium tosylate (5 mg/kg every 6 hours for 48-72 hours)
Trial: 3897961
Drug: Cefotaxime (CTX)
DrugBank: Cefotaxime (DB00493)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefotaxime (CTX) 20 mg/kg, two intravenous injections
Trial: 26278063
Drug: Basal insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Basal insulin peglispro
Trial: 20227541
Drug: Mifepristone and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone and misoprostol administration intervals between 0 and 72 hours
Trial: 20227541
Drug: Mifepristone and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone and misoprostol administration intervals less than 8 hours
Trial: 20227541
Drug: Longer administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Longer administration intervals (greater than 8 hours)
Trial: 18090070
Drug: Low-dose ketamine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose ketamine (0.5 mg/kg bolus, followed by 4 microg/kg/min infusion)
Trial: 15145973
Drug: Lumiracoxib (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumiracoxib (400 mg daily)
Trial: 11920261
Drug: Conventional first-line
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional first-line chemotherapy (ACVBP)
Trial: 11920261
Drug: Alternating chemotherapy
RxNorm normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternating chemotherapy regimen (VIMMM with ACVBP for induction and VIM and ACVM in consolidation)
Trial: 9825369
Drug: i.v. propafenone,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. propafenone, 2 mg/kg bolus, followed by 0.0078 mg/kg/min
Trial: 9825369
Drug: p.o. propafenone,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: p.o. propafenone, 600 mg p.o. in a single dose
Trial: 9825369
Drug: p.o. flecainide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: p.o. flecainide, 300 mg p.o. in a single dose
Trial: 9825369
Drug: i.v. amiodarone,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. amiodarone, 5 mg/kg bolus, followed by 1.8 g/24 hours
Trial: 2655044
Drug: Nitrendipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrendipine (20 mg/day, 40 mg single dose, 20 mg twice a day)
Trial: 22248871
Drug: Valsartan/hydrochlorothiazide (160/12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan/hydrochlorothiazide (160/12.5 mg titrated to 320/25 mg)
Trial: 22248871
Drug: Amlodipine/hydrochlorothiazide (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine/hydrochlorothiazide (5 mg and 10 mg of amlodipine added at weeks 8 and 12)
Trial: 20591625
Drug: Creatine (0.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine (0.03 g · kg(‐1) · d(‐1); n = 10, 4 women)
Trial: 19998583
Drug: Fixed dose
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dose combination tablet of lamivudine and stavudine
Trial: 19998583
Drug: Concurrent administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concurrent administration of lamivudine tablet and stavudine capsule
Trial: 15687112
Drug: Low bicarbonate
RxNorm normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low bicarbonate (LB; 27 mmol/l)
Trial: 15687112
Drug: Standard bicarbonate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard bicarbonate (SB; 35 mmol/l)
Trial: 15687112
Drug: High bicarbonate
RxNorm normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High bicarbonate (HB; 39 mmol/l)
Trial: 12031750
Drug: Diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac sodium 75 mg (Group D)
Trial: 12031750
Drug: Ketorolac tromethamine
RxNorm normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketorolac tromethamine 60 mg (Group K)
Trial: 10086794
Drug: GM‐CSF 250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GM‐CSF 250 microg/m2 for 3 days followed by G‐CSF 10 microg/kg for 3 days (GM+G)
Trial: 10086794
Drug: G‐CSF 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF 10 microg/kg for 6 days (G‐alone)
Trial: 10086794
Drug: Intermediate-dose melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermediate-dose melphalan (IDM 100 mg/m2)
Trial: 6355056
Drug: Topical acyclovir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical acyclovir cream
Trial: 35135
Drug: Intravenous cimetidine
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous cimetidine administration
Trial: 35135
Drug: Intragastric antacid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intragastric antacid instillation
Trial: 21900786
Drug: 4-l polyethylene
RxNorm normalized name: polyethylene glycol 3350
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-l polyethylene glycol (PEG) solution (Klean-prep)
Trial: 21900786
Drug: 2-l PEG
RxNorm normalized name: Iron(2+) L-ascorbate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-l PEG solution + ascorbic acid (Moviprep)
Trial: 21900786
Drug: sodium phosphate
RxNorm normalized name: Sodium Phosphate
DrugBank: Sodium nitrate (DB15952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sodium phosphate (NaP) solution, Phosphoral
Trial: 15008996
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine oestrogen (CEE) 0.625 mg/day
Trial: 15008996
Drug: Droloxifene 60
RxNorm normalized name: Droloxifene
DrugBank: Droloxifene (DB15641)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droloxifene 60 mg/day
Trial: 11426524
Drug: ABLC (3-5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABLC (3-5 mg/kg/day for 10 days)
Trial: 11426524
Drug: AmBisome (3-5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AmBisome (3-5 mg/kg/day for 15 days)
Trial: 2692092
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose inhaled beclomethasone dipropionate (2000 micrograms day‐1 for two weeks)
Trial: 1192701
Drug: Oral sodium
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral sodium loading (100 mmol)
Trial: 1192701
Drug: Intravenous sodium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous sodium loading (100 mmol)
Trial: 30734413
Drug: Lidocaine spray
RxNorm normalized name: lidocaine Mucosal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine spray (10% lidocaine, 8 puffs, 80 mg total, 3 minutes before procedure)
Trial: 30734413
Drug: Placebo spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo spray (0.8 mL normal saline, 3 minutes before procedure)
Trial: 21636546
Drug: Oral iloprost
RxNorm normalized name: Iloprost
DrugBank: Iloprost (DB01088)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral iloprost
Trial: 16490478
Drug: Baclofen (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baclofen (30 mg/day for 10 consecutive days)
Trial: 16490478
Drug: Diazepam (0.5-0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (0.5-0.75 mg/kg/day for 6 consecutive days, tapering the dose by 25% daily from day 7 to day 10)
Trial: 11421996
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of BDP (1000 microg)
Trial: 11421996
Drug: Inhaled BDP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled BDP (1000 microg)
Trial: 11421996
Drug: Oral BDP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral BDP (4000 microg)
Trial: 11421996
Drug: Intranasal BDP
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal BDP (1344 microg)
Trial: 11421996
Drug: Inhaled BDP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled BDP with charcoal
Trial: 11421996
Drug: Oral and
RxNorm normalized name: Tridate, oral and rectal kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral and intranasal BDP
Trial: 11421996
Drug: Inhaled BDP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled BDP
Trial: 27013431
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose + adjuvant (100 μg antigen + AlOH)
Trial: 27013431
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose + adjuvant (100 μg antigen + AlOH) administered on Days 0-7-30
Trial: 27013431
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose (50 μg antigen) with or without aluminum hydroxide (AlOH) adjuvant
Trial: 24998111
Drug: 2 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 μg kg(‐1) remifentanil (Group 1, n=25)
Trial: 24998111
Drug: 2 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 μg kg(‐1) remifentanil and 1 mg kg(‐1) lidocaine (Group 2, n=25)
Trial: 24998111
Drug: 2 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 μg kg(‐1) remifentanil (Group 1)
Trial: 24998111
Drug: 2 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 μg kg(‐1) remifentanil and 1 mg kg(‐1) lidocaine (Group 2)
Trial: 12559244
Drug: Peripheral repetitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peripheral repetitive magnetic stimulation (rMS) - 10 sessions, each lasting 20 minutes, with 4000 magnetic stimuli administered in 5s trains at 20Hz at the trigger point.
Trial: 12559244
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment - application of a non-functioning ultrasound therapy device to the trigger point.
Trial: 8039873
Drug: Preimmunization level
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preimmunization level of natural HibCP antibodies
Trial: 24151766
Drug: Cinacalcet and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinacalcet and low doses of vitamin D analogs
Trial: 24151766
Drug: Larger, varying
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Larger, varying doses of vitamin D
Trial: 16784346
Drug: Barriers to
RxNorm normalized name: Valiant Barrier
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Barriers to entry (e.g., misspelled brand name)
Trial: 15303768
Drug: Radiotherapy +
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiotherapy + paclitaxel (30 mg/m2 weekly, median six cycles)
Trial: 15303768
Drug: Radiotherapy +
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiotherapy + paclitaxel (60 mg/m2 weekly, median six cycles)
Trial: 28625627
Drug: Toxicity-Adjusted Dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toxicity-Adjusted Dosing (TAD) of cisplatin + etoposide
Trial: 28625627
Drug: Fixed Dosing
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed Dosing (FD) of cisplatin + etoposide
Trial: 26251244
Drug: 70 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 70 μg/kg desmoteplase
Trial: 26251244
Drug: 90 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 μg/kg desmoteplase
Trial: 23052033
Drug: ACT-077825 (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACT-077825 (500 mg, 1000 mg)
Trial: 23052033
Drug: ACT-077825 (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACT-077825 (500 mg)
Trial: 23052033
Drug: ACT-077825 (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACT-077825 (1000 mg)
Trial: 22073219
Drug: Eplerenone (25-50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eplerenone (25-50 mg once daily for 8 weeks)
Trial: 18926569
Drug: Dispersible artemether-lumefantrine
RxNorm normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dispersible artemether-lumefantrine tablets
Trial: 18926569
Drug: Crushed artemether-lumefantrine
RxNorm normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crushed artemether-lumefantrine tablets
Trial: 16446752
Drug: rosiglitazone (RSG)
DrugBank: Rosiglitazone (DB00412)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rosiglitazone (RSG) 8 mg
Trial: 16446752
Drug: rosiglitazone (RSG)
DrugBank: Rosiglitazone (DB00412)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rosiglitazone (RSG) 2 mg
Trial: 16446752
Drug: rosiglitazone (RSG)
DrugBank: Rosiglitazone (DB00412)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rosiglitazone (RSG) 4 mg
Trial: 16446752
Drug: rosiglitazone (RSG)
DrugBank: Rosiglitazone (DB00412)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rosiglitazone (RSG) 2, 4, or 8 mg
Trial: 12587890
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate (NaHCO3) ingestion (0.3 g x kg body mass(-1))
Trial: 8213103
Drug: EE/NET formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EE/NET formulation (EE 35 micrograms and norethisterone 0.5 mg on days 1‐7 and days 17‐21, elevated to 1.0 mg during days 8‐16)
Trial: 8213103
Drug: EE/LGN formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EE/LGN formulation (EE 30 micrograms on days 1‐6 and days 12‐21, 40 micrograms on days 7‐11, phased levonorgestrel: 50 micrograms (days 1‐6), 75 micrograms (days 7‐11), and 125 micrograms (days 12‐21)
Trial: 3777330
Drug: Gentamicin (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin (single dose)
Trial: 30572916
Drug: One cycle
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One cycle of GnRH agonist
Trial: 30572916
Drug: Two cycles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two cycles of GnRH agonist
Trial: 27793181
Drug: Internet-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based cognitive behavioural therapy (ICBT) programme FearFighter™, nine sessions with weekly telephone contact
Trial: 27793181
Drug: Internet-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based cognitive behavioural therapy (ICBT) programme FearFighter™
Trial: 17869296
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg vardenafil in patients with ASIA classification A and spinal cord injury above T6
Trial: 3109142
Drug: Nisoldipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nisoldipine (20 mg orally t.i.d. for 3 patients, 20 mg b.i.d. for 5 patients)
Trial: 3109142
Drug: Captopril (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (25 mg orally t.i.d.)
Trial: 29636355
Drug: Treatment-as-usual control
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-as-usual control (n=60)
Trial: 28768069
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen (HBO₂) at 1.5 ATA for 60 minutes daily for 40 sessions
Trial: 28768069
Drug: Sham chamber
RxNorm normalized name: HOLDING CHAMBER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham chamber sessions at 1.2 ATA, air for 60 minutes daily for 40 sessions
Trial: 25179788
Drug: Plerixafor (MZ)
RxNorm normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Plerixafor (MZ) given as a single dose to 30 poor mobilizers (PM)
Trial: 25179788
Drug: G‐CSF +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF + Plerixafor (MZ)
Trial: 22455385
Drug: Topical 1%
RxNorm normalized name: fluoride topical 1% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 1% oxytetracycline hydrochloride three times a day for 1 week
Trial: 10634964
Drug: Micronised fenofibrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronised fenofibrate 200 mg daily
Trial: 3529953
Drug: Enteric-coated aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric-coated aspirin (325 mg)
Trial: 28089180
Drug: Plain aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plain aspirin (325 mg)
Trial: 2037955
Drug: Metronidazole treatment
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metronidazole treatment (250 mg tid for 7 days) plus debridement
Trial: 2037955
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment plus debridement (positive control)
Trial: 2037955
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (positive control)
Trial: 6786566
Drug: Branded analgesic
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Branded analgesic tablets
Trial: 6786566
Drug: Unbranded analgesic
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unbranded analgesic tablets
Trial: 6786566
Drug: Placebo (inert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (inert formulation)
Trial: 6786566
Drug: Active formulation
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active formulation (branded)
Trial: 31426749
Drug: ezetimibe/simvastatin 10/10 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ezetimibe/simvastatin 10/10 mg
Trial: 31426749
Drug: rosuvastatin 10 mg
RxNorm normalized name: rosuvastatin 10 MG
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: rosuvastatin 10 mg
Trial: 28337563
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) combined with facial exercise treatment
Trial: 28337563
Drug: Facial exercise
RxNorm normalized name: sulfur
DrugBank: Octasulfur (DB09353)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Facial exercise treatment alone
Trial: 21867390
Drug: Enoxaparin 20
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 20 mg/0.2 ml subcutaneous (sc) 2 hr before surgery
Trial: 17760592
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy with 5-aminolevulinic acid or indocyanine green
Trial: 17760592
Drug: New procedural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New procedural therapies (radiofrequency, light or laser, photodynamic therapy)
Trial: 15500555
Drug: 5 MU
RxNorm normalized name: MULTISTIX 5 MULTIPLE TEST STRIP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 MU daily of IFN alfa‐2b for 4 weeks followed by IFN (5 MU TIW) plus ribavirin (1000/1200 mg/daily) for 48 weeks (group 1)